Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBIT Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBIT Margin for 11 consecutive years, with 428.86% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 63101.0% to 428.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 651.67% through Dec 2025, up 27143.0% year-over-year, with the annual reading at 651.67% for FY2025, 27143.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 428.86% at Intellia Therapeutics, up from 808.86% in the prior quarter.
  • The five-year high for EBIT Margin was 212.18% in Q4 2021, with the low at 23997.67% in Q3 2021.
  • Average EBIT Margin over 5 years is 2093.34%, with a median of 808.86% recorded in 2025.
  • The sharpest move saw EBIT Margin plummeted -2387120bps in 2021, then skyrocketed 2320217bps in 2022.
  • Over 5 years, EBIT Margin stood at 212.18% in 2021, then crashed by -31bps to 278.7% in 2022, then plummeted by -292bps to 1093.29% in 2023, then rose by 3bps to 1059.86% in 2024, then skyrocketed by 60bps to 428.86% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 428.86%, 808.86%, and 772.17% for Q4 2025, Q3 2025, and Q2 2025 respectively.